In April 2024, a year after starting my GLP-1 journey, I was down 133 pounds
It provides a reliable oral option that can stabilize appetite and cravings during medication changes or insurance challenges
Oral Formulations The only available oral GLP-1 receptor agonist is semaglutide (Rybelsus, Novo Nordisk)
Starting with a lower dose and gradually increasing helps reduce common side effects and improves patient comfort and adherence to the regimen
It is important to contextualise these results carefully: Phase 2 trials involve relatively small, controlled populations and are not sufficient on their own to establish a medicine's full safety profile or its suitability for broad clinical use
WEIGHT LOSS: In clinical trials comparing both of these peptide therapies, the following results were recorded: Because it is the newest drug in the class and has the dual receptor modality, GLP-1/GIP is considered the best medication of the two